ArticleFrontiers in immunology2023

Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.

Daidi Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.